Diu is a Postdoctoral Scholar at the Memorial Sloan Kettering Cancer Center in New York City. Her research focuses on the roles of RNA binding proteins in hematopoiesis and leukemia.

Before moving to New York, Diu completed her PhD in Clinical Laboratory Sciences from the University of Oxford and obtained a MSc degree in Biomolecular Sciences from the Vrije University of Amsterdam.

Diu first joined the Oxford branch of the Innovation Forum in a Business Development Executive role and is currently leading New York City branch.

Arikha Moses has 15+ years of experience creating and leading Life Science companies. She is currently the CEO of Concarlo Holdings, a biotech based in Brooklyn which is developing new products that target and treat metastatic cancer.

Dr. Moses started her career at a seed-stage venture firm Athena Ventures, where she was responsible for sourcing, building, and managing early-stage life science companies, including TyRx, that, was sold to Medtronic for $160MM. She then worked with the venture capital firm the Vertical Group, where she founded and led Galatea Surgical, a plastic surgery company, through clinical studies and commercial product sales. She has also served the EIR of Columbia Technology Ventures.

Dr. Moses received a Ph.D. in Chemistry from Yale University and a BA with Honors in Chemistry from Brandeis University

Kaja Wasik is Co-Founder and Chief Science Officer at Gencove, a technology company that serves as a platform for discovery in Population Genetics. Gencove’s platform is currently being used by biobanks (Weizmann Institute), pharma companies (GSK), citizen science projects (Darwin's Arc), and academic researchers (Harvard, Stanford, Oxford etc.)

During her doctorate, Kaja studied mobile genetic elements and the genomic architecture of species with regenerative properties. After her Ph.D., Kaja joined New York Genome Center as a Postdoctoral Fellow. There, she laid the foundation for the spin-off Gencove, which she co-founded together with her advisor and Professor in statistical genetics, Joseph Pickrell.

Kaja received her M.A. in political science and M.S. in Biology at the University of Warsaw and completed her Ph.D. in molecular biology at Cold Spring Harbor Laboratory.

Sid Angle, is the President & Chief Executive Officer of Regenosine a company that is developing a promising treatment for osteoarthritis.

Sid’s career in musculoskeletal research & development spans 15 years. He played an integral role in the acquisition of a synthetic biomaterials start-up by Zimmer Biomet. He was then R&D Manager for their Global Biologics business and has successfully commercialized several orthopedic medical devices and combination therapies. In 2017 he joined NYU Langone Medical Center as Business Development Manager and he is responsible for managing NYU’s medical device accelerator program to incubate disruptive technologies using stage gate development while progressively de-risking the projects.

He received his M.S. in bioengineering at the University of Illinois Ph.D. in Rush University where he graduated with honors.

Jean H. Kim has over 20 years of executive search experience in Life Science industry. She began her career in public service in New York City but soon transitioned into pharmaceutical recruitment with a boutique firm specializing in biometrics. Over 18 years, Jean built and managed a group recruitment in information technology and data sciences, eventually expanding to include clinical development and regulatory functions for companies like Merck and Biogen.

In 2014 Jean established her own consultancy, AlphaKAP Strategic Search, to work with start-up companies and investment firms filling various C- level functions. Jean joined Ward Howell International as a Partner in 2017 and has focused her efforts into cell and gene therapy, medical devices, and neuroscience.

A California native, Jean received her BA in social science from UC Berkeley and her Masters Degree in Public Policy from Harvard University.